Abstract Objective To develop a Canadian consensus document on maternal screening for
fetal aneuploidy (eg, Down syndrome and trisomy 18) in singleton pregnancies. Options …

Purpose: To determine whether maternal plasma cell–free DNA sequencing can effectively
identify trisomy 18 and 13. Methods: Sixty-two pregnancies with trisomy 18 and 12 with …

Background: Down syndrome is one of the most important causes of mental retardation in
the population. In the absence of prenatal screening and diagnosis, prevalence at birth in …

Objective To determine whether non‐invasive prenatal testing by maternal plasma DNA
sequencing can uncover all fetal chromosome aneuploidies in one simple sequencing …

The trisomy 18 and trisomy 13 syndromes represent important and common conditions of
human aneusomy. Together, their combined prevalence in live born infants approaches …

This study examines the relationship between maternal weight and serum levels of alpha‐
fetoprotein, unconjugated oestriol, and human chorionic gonadotropin in a population of 47 …

Abstract Objective: To develop a Canadian consensus document with recommendations on
maternal screening for fetal aneuploidy (eg, Down syndrome and trisomy 18) in pregnancy …

OBJECTIVE: To evaluate the performance of first-and second-trimester screening methods
for the detection of aneuploidies other than Down syndrome. METHODS: Patients with …

Cell-free fetal DNA in the maternal circulation is a potential noninvasive marker for fetal
aneuploidies. In previous studies with Y DNA as a fetal-specific marker, levels of circulating …

OBJECTIVE: To estimate detection rates for aneuploidy by first-trimester and sequential
screening. METHODS: The study included women with singleton pregnancies who …